Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis

BACKGROUND AND AIMS: Vedolizumab is an anti-α4β7 antibody approved for the treatment of ulcerative colitis [UC]. Although it is assumed that vedolizumab blocks intestinal homing of lymphocytes, its effects on different intestinal cell populations are not fully stablished. In order to establish the u...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Crohns Colitis
Main Authors: Veny, Marisol, Garrido-Trigo, Alba, Corraliza, Ana M, Masamunt, Maria C, Bassolas-Molina, Helena, Esteller, Miriam, Arroyes, Montserrat, Tristán, Eva, Fernández-Clotet, Agnès, Ordás, Ingrid, Ricart, Elena, Esteve, Maria, Panés, Julian, Salas, Azucena
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7944518/
https://ncbi.nlm.nih.gov/pubmed/32926095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjaa178
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados